Molecular Partners AG Sponsored ADR (NASDAQ:MOLN – Free Report) – HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for shares of Molecular Partners in a report issued on Monday, March 16th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.35) per share for the quarter, up from their previous estimate of ($0.41). HC Wainwright has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for Molecular Partners’ current full-year earnings is ($1.93) per share. HC Wainwright also issued estimates for Molecular Partners’ Q2 2026 earnings at ($0.35) EPS, Q3 2026 earnings at ($0.36) EPS, Q4 2026 earnings at ($0.37) EPS, FY2026 earnings at ($1.42) EPS, Q1 2027 earnings at ($0.38) EPS, Q2 2027 earnings at ($0.34) EPS, Q3 2027 earnings at ($0.31) EPS, Q4 2027 earnings at ($0.33) EPS and FY2027 earnings at ($1.35) EPS.
Molecular Partners (NASDAQ:MOLN – Get Free Report) last announced its earnings results on Thursday, March 12th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.03).
Check Out Our Latest Report on Molecular Partners
Molecular Partners Price Performance
Shares of NASDAQ:MOLN opened at $4.57 on Wednesday. Molecular Partners has a 1 year low of $3.36 and a 1 year high of $5.36. The firm has a market capitalization of $184.46 million, a PE ratio of -2.30 and a beta of 1.03. The business’s 50 day moving average price is $4.54 and its 200-day moving average price is $4.19.
Institutional Trading of Molecular Partners
An institutional investor recently bought a new position in Molecular Partners stock. SmartHarvest Portfolios LLC purchased a new stake in shares of Molecular Partners AG Sponsored ADR (NASDAQ:MOLN – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 12,311 shares of the company’s stock, valued at approximately $54,000. 26.55% of the stock is currently owned by institutional investors.
Key Molecular Partners News
Here are the key news stories impacting Molecular Partners this week:
- Positive Sentiment: HC Wainwright raised quarterly and full‑year EPS estimates for 2026 and 2027 (multiple quarters revised toward smaller losses), upgraded FY2026 from ($1.70) to ($1.42) and FY2027 from ($1.64) to ($1.35), and reiterated a “Buy” rating with a $13 price target — a clear catalyst supporting today’s uptick. MarketBeat MOLN coverage
- Positive Sentiment: News outlets picked up HC Wainwright’s Buy call, amplifying investor attention and likely contributing to buying pressure. Molecular Partners Earns Buy Rating from HC Wainwright
- Neutral Sentiment: Molecular Partners will present three posters at the AACR 2026 Annual Meeting (April) highlighting its DARPin therapeutic programs — good for scientific credibility and long‑term investor awareness but unlikely to produce immediate revenue or clinical readouts. Company Announces AACR Posters
About Molecular Partners
Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.
The company’s development pipeline spans infectious diseases, ophthalmology and oncology.
Further Reading
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
